Incyte (INCY) Q3 2025 10-Q Quarterly Report
Filed: Oct 28, 2025Period ending Sep 30, 2025
Industrials
Services-Commercial Physical & Biological ResearchSEC EDGAR Incyte (INCY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Incyte Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $1.37B Q3 2025, up 20% YoY from $1.14B in Q3 2024, driven by JAKAFI $791.1M (+$49.9M) and OPZELURA $188M (+$48.7M) growth
- • Net income $424.2M Q3 2025 vs $106.5M Q3 2024; Operating margin not explicitly stated but net income increased ~298% YoY
- • Best performing product JAKAFI: $791.1M revenue Q3 2025 (+7% YoY); Worst performance not separately quantified but legacy drugs lower growth
- • Operating cash flow $870.2M YTD Sept 2025 vs -$45.9M YTD Sept 2024, driven by contract dispute settlement and Escient acquisition impacts
- • Management notes ongoing evaluation of new FASB accounting standards; expects impact from government rebates on future revenues; confident in liquidity and capital sufficiency
Risk Factors
- • New risk: Increased patient access challenges from PBM rebate negotiations, especially for OPZELURA, triggered by ongoing formulary coverage agreements
- • Material update: FDA added boxed warnings for JAKAFI and OPZELURA in Sept 2021 citing risks of cardiovascular events, thrombosis, mortality negatively impacting sales prospects
- • Regulatory risk: Potential loss or modification of marketing approval due to adverse safety events or regulatory agency enforcement, including prior EMA ICLUSIG label changes
- • Operational risk: Heavy reliance on limited specialty pharmacies and wholesalers for product distribution poses risk of revenue disruption if distribution partners exit or change terms
- • Financial risk: Pricing and reimbursement pressures from government programs, insurers, and 340B program growth may reduce product pricing and profitability
Incyte Q3 2025 Quarterly FinancialsXBRL
Revenue
$1.4B
▲ +20.0% YoY▲ +12.4% QoQ
Net Income
$424M
▲ +298.4% YoY▲ +4.7% QoQ
Operating Margin
32.5%
▲ +1963bp YoY▼ -1116bp QoQ
Net Margin
31.1%
▲ +2170bp YoY▼ -227bp QoQ
ROE
9.1%
Total Assets
$6.3B
EPS (Diluted)
$2.11
▲ +379.5% YoY▲ +3.4% QoQ
Operating Cash Flow
$559M
▲ +79.9% YoY▲ +1150.3% QoQ
Source: XBRL data from Incyte Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Incyte Quarterly Reports
Get deeper insights on Incyte
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.